Dermata Therapeutics Inc. (DRMA)
NASDAQ: DRMA
· Real-Time Price · USD
0.60
0.01 (2.39%)
At close: Jun 27, 2025, 1:59 PM
2.39% (1D)
| Bid | 0.43 |
| Market Cap | 3.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.46M |
| EPS (ttm) | -1.42 |
| PE Ratio (ttm) | -0.43 |
| Forward PE | -0.6 |
| Analyst | Buy |
| Ask | 0.77 |
| Volume | 65,889 |
| Avg. Volume (20D) | 218,441 |
| Open | 0.60 |
| Previous Close | 0.59 |
| Day's Range | 0.59 - 0.61 |
| 52-Week Range | 0.57 - 5.00 |
| Beta | 0.57 |
About DRMA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DRMA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DRMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+5.19%
Dermata shares are trading higher after the compan...
Unlock content with
Pro Subscription
6 months ago
+19.01%
Dermata Therapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)"
2 months ago · accessnewswire.com
Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGA...
